Merck Receivables 2010-2024 | MRK

Merck receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Merck receivables for the quarter ending September 30, 2024 were $11.381B, a 9.5% increase year-over-year.
  • Merck receivables for 2023 were $10.349B, a 9.51% increase from 2022.
  • Merck receivables for 2022 were $9.45B, a 2.38% increase from 2021.
  • Merck receivables for 2021 were $9.23B, a 35.68% increase from 2020.
Merck Annual Receivables
(Millions of US $)
2023 $10,349
2022 $9,450
2021 $9,230
2020 $6,803
2019 $6,778
2018 $7,071
2017 $6,873
2016 $7,018
2015 $6,484
2014 $6,626
2013 $7,184
2012 $7,672
2011 $8,261
2010 $7,344
2009 $6,603
Merck Quarterly Receivables
(Millions of US $)
2024-09-30 $11,381
2024-06-30 $11,642
2024-03-31 $11,366
2023-12-31 $10,349
2023-09-30 $10,394
2023-06-30 $11,030
2023-03-31 $10,415
2022-12-31 $9,450
2022-09-30 $9,482
2022-06-30 $9,643
2022-03-31 $9,828
2021-12-31 $9,230
2021-09-30 $8,571
2021-06-30 $7,843
2021-03-31 $8,235
2020-12-31 $6,803
2020-09-30 $8,422
2020-06-30 $7,577
2020-03-31 $8,182
2019-12-31 $6,778
2019-09-30 $8,442
2019-06-30 $7,964
2019-03-31 $7,608
2018-12-31 $7,071
2018-09-30 $7,374
2018-06-30 $7,287
2018-03-31 $7,245
2017-12-31 $6,873
2017-09-30 $7,671
2017-06-30 $7,439
2017-03-31 $7,066
2016-12-31 $7,018
2016-09-30 $7,364
2016-06-30 $6,916
2016-03-31 $6,850
2015-12-31 $6,484
2015-09-30 $6,414
2015-06-30 $6,510
2015-03-31 $6,670
2014-12-31 $6,626
2014-09-30 $6,515
2014-06-30 $7,022
2014-03-31 $7,188
2013-12-31 $7,184
2013-09-30 $7,578
2013-06-30 $7,779
2013-03-31 $7,965
2012-12-31 $7,672
2012-09-30 $7,952
2012-06-30 $8,152
2012-03-31 $8,726
2011-12-31 $8,261
2011-09-30 $8,136
2011-06-30 $8,475
2011-03-31 $7,955
2010-12-31 $7,344
2010-09-30 $7,298
2010-06-30 $6,276
2010-03-31 $7,498
2009-12-31 $6,603
2009-09-30 $3,804
2009-06-30 $3,663
2009-03-31 $3,570
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $260.350B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51